REFRACTORY MARGINAL ZONE LYMPHOMA
Clinical trials for REFRACTORY MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo targets Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New Three-Drug cocktail aims to tackle tough lymphomas
Disease control OngoingThis study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Three-Drug cocktail targets Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial is testing the safety and best dose of a three-drug combination (venetoclax, lenalidomide, and rituximab) in patients with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. The study enrolled only 4 participants to …
Matched conditions: REFRACTORY MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 26, 2026 17:05 UTC